EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board
developer and manufacturer of customized enzymes announced today the
appointment of two seasoned biotechnology executives to its Advisory Board.
The new appointees are Dr.
Codexis) and currently CEO of Solidus Biosciences, and Dr.
Miltenyi Biotec. Dr.
Wachstumsfonds, will continue to serve on the realigned Advisory Board.
With its current members, EUCODIS Bioscience’s Advisory Board will focus
on providing guidance and advice in the areas of strategy, market and
organization, strengthening the skills and experience of EUCODIS Bioscience’s
management team.
“I am extremely pleased to welcome two distinguished executives of the
biotechnology industry to our Advisory Board,” said
EUCODIS Bioscience. “Dr. Rozzell as a successful founder and entrepreneur in
the enzyme industry, and Dr. Bethke with entrepreneurial mindset and his
track record in biotechnology manufacturing and operations, bring to EUCODIS
Bioscience a wealth of hands-on experience and operational knowledge. Having
these seasoned executives on our Advisory Board will be a tremendous asset to
the Company as our customer base is growing rapidly. We will continue to
expand our portfolio, and are aggressively addressing new business
opportunities in the pharmaceutical, bioproducts, cosmetics, and other
industries.”
Dr.
providing research and analytical services to the pharmaceutical and
cosmetics industry, enhancing their development productivity. Prior to
joining Solidus as CEO, he was the Founder and CEO of enzyme developer
BioCatalytics, which he grew to a leader in its field until the company was
successfully sold to Codexis in 2007. Before founding BioCatalytics, Dr.
Rozzell was President and COO of Exogene.
Dr.
Biotec in 1994, he was responsible for the development and production of
therapeutic monoclonal antibodies at Biotest, a German pharmaceutical company.
Dr.
venture capital company. He has 10 years of experience as an investment
manager, overseeing the whole investment life-cycle, from deal acquisition
through active management of portfolio companies to financing and
implementation of the exit strategy.
Harald Schuerz is CEO of Wiener Wachstumsfonds, an Austrian venture
capital fund focusing on innovative, fast growing companies. Before joining
Athena, he held executive positions at leading Austrian banks where he was
responsible for venture capital investments and international financing.
About EUCODIS Bioscience
EUCODIS Bioscience provides enzymes to the chemical, health care, and
other industries, and offers custom-engineering and custom-manufacturing
services.
Customers use EUCODIS Bioscience’ enzymes and services to make their
manufacturing processes more efficient and cleaner and to introduce products
with superior properties. The Company’s technology of in vivo-recombination
is a proven tool for the directed evolution of enzymes that perform to
customers’ specific requirements.
Enzymes are proteins that catalyze highly specific chemical reactions,
offering a safer, cleaner, and competitive alternative to traditional
chemistry. They are at the center of industrial, or “white” biotechnology, a
fast growing industry segment with sales in excess of
Led by an experienced management team, EUCODIS Bioscience is backed by
Austrian and German institutional venture capital funds, founders, and
private investors. The Company is headquartered in
subsidiary in
For more information, please visit http://www.eucodisbioscience.com
Company contact EUCODIS Bioscience:
Thomas Fischer, MBA
CEO
EUCODIS Bioscience
Campus Vienna Biocenter II
Viehmarktgasse 2 a/ 2 OG
A-1030 Vienna
AUSTRIA
+43-1-8900804
office@eucodisbioscience.com
Media contact EUCODIS Bioscience:
Frank Butschbacher
Investor Relations & Communications
http://www.butschbacher.net
+43-650-7844940
office@butschbacher.net
SOURCE EUCODIS Bioscience